Cargando…
Cisplatin Resistance: Genetic and Epigenetic Factors Involved
Cisplatin (CDDP) is the drug of choice against different types of cancer. However, tumor cells can acquire resistance to the damage caused by cisplatin, generating genetic and epigenetic changes that lead to the generation of resistance and the activation of intrinsic resistance mechanisms in cancer...
Autores principales: | Lugones, Yuliannis, Loren, Pía, Salazar, Luis A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599500/ https://www.ncbi.nlm.nih.gov/pubmed/36291573 http://dx.doi.org/10.3390/biom12101365 |
Ejemplares similares
-
MicroRNAs Involved in Intrinsic Apoptotic Pathway during Cisplatin-Induced Nephrotoxicity: Potential Use of Natural Products against DDP-Induced Apoptosis
por: Loren, Pía, et al.
Publicado: (2022) -
Epigenetic Mechanisms Involved in Cisplatin-Induced Nephrotoxicity: An Update
por: Loren, Pía, et al.
Publicado: (2021) -
Mitochondrial Involvement in Cisplatin Resistance
por: Cocetta, Veronica, et al.
Publicado: (2019) -
The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer
por: O'Byrne, Kenneth J., et al.
Publicado: (2011) -
Inhibition and counterinhibition of Surfacen, a clinical lung surfactant of natural origin
por: Lugones, Yuliannis, et al.
Publicado: (2018)